Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still not too late Sonic, today’s volume speaks volumes. I normally flip some of this stock when it hits 14-15, but I think those days are behind us.
This is what I’m taking about !
Amen brother
Can’t believe we’re still digits here
Anybody else here into GTHX?
Amen brother
Savvy move Cosa, a lot of posters here got a little offended when I sold a chunk of my AUPH shares at $15, but buying back around 11 is over a 25% increase.I don’t see magical things happening with Q2 results, but it should at least get us back in the mid teens.
BR loves Max, awwwwwww
Right on Gregg
I’m guessing it’s linked to Q2 results.AUPH always reports 1 month after quarter end and are waiting 2 months this time.If they had something to pound their chests about, they wouldn’t have chosen to sit on the news for an extra month.
I hope I’m wrong.
Good post Jess
Definitely an odd statement
Cramer’s a brilliant analyst, but he sucks at Spec stocks, he’s all about best of breed and balance sheets.
GSK under fire for underperformance, poor management. Suboptimal drug portfolio. I know a place they can buy a turn key but kicking money maker. Can you imagine how quickly VOC would sell neatly tucked away in a Glasgow box?
Good move Nsom
From 14 to 12.9 yet again, nobody’s more long on AUPH than me, but the stock is insanely predictable, are you guys finally getting this?
Hopefully w3 have some real Q2 numbers
5 mil shares for 8.55
Ji making it happen !
Ha, so true Jess!
“Insider buying “
Director
Informative Buy
$50,521.00
a month ago
R Hector Mackay-Dunn
Director
Informative Buy
$50,529.00
a month ago
Leversage Jill
Director
Informative Buy
$27,375.00
a month ago
Matthew Maxwell Donley
Ex VP, Intern'l Operations
Informative Buy
$99,693.00
a month ago
Peter Greenleaf
Chief Executive Officer, Director
Informative Buy
$54,891.07
a month ago
Martin Michael Robert
Chief Business Officer
Informative Buy
$60,400.00
a month ago
Max Donley
Executive Vice-President - Operations
Informative Buy
$99,738.54
a month ago
Jill Diane Leversage
Director
Informative Buy
$27,389.25
a month ago
Peter Greenleaf
Chief Executive Officer
Informative Buy
$54,891.31
a month ago
Michael Robert Martin
Divisional Vice-President
Uninformative Sell
$60,400.00
a month ago
Robert Huizinga
Divisional Executive Vice-President
Uninformative Sell
$120,800.00
a month ago
Joseph Miller
Chief Financial Officer
Informative Buy
$9,740.00
a month ago
Huizinga Robert Bindert
Ex Vice President Of Research
Informative Buy
$120,800.00
a month ago
Zzaatt for prez !,
Ha, I didn’t know he had any.
Paying peeps in stock is always a catalyst for northward propulsion and I can’t tell you how many buyouts I’ve seen that start with an emphasis on mergers and acquisitions
Exactly grasshopper, she acquired , didn’t purchasethe shares…where did I lose ya?
A mergers and acquisitions pro, doesn’t mean a BO is off the table at all…..she did JUST acquire 53,291 shares for 12.86 a share
AUPH blowing up my inbox
Zep, she was voted in, you should have received an email to vote, so it really wasn’t that quiet but……this is why her addition should be positive.
“Dr. Balakrishnan leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing”
Without a doubt Jess
I think the only thing we can all agree on is that we should be buying more AUPH at these levels.
Newbie, it’s only obvious because the stock has been systematically do this since February. I’m been gambling on the fact that revenues and sales are low and PG isn’t giving guidance , BUT the day you flip 50% of your stock, that’s the day it pops.Like everything else, flipping is only good in moderation.
Soon, the stock will go back up into the high teens, the press releases will be sexier and the volume won’t be floating at a mere 1-3 million……ahhhhh just thinking about it
This is actually pretty funny BR.
It’s a win either way Merc, what a great dilemma
The beast has awoken ….
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers.
Jess is back in the house !
I’m buying here, who’s in ?
This reason for my previous recommendation.
Was anybody else on the call today?
I normally agree with ya Jess, but not on this one. When AUPH received FDA approval SIX months ago, then dropped from 20 to the teens it was pretty obvious to me that the stock wasn’t going to budge until they get some real sales revenue. I’m sure AUPH has turned down some low ball offers because companies are offering them low prices since they have little revenue.
I’ve significantly added a large number of shares to my position by only flipping 10% of my position in AUPH, so my share count is much higher than it was in January, again with no money out of pocket.this AUPH board has a handful of good posters, many which are extremely frustrated, so flipping is my suggestion to them.
Jess, you missed my point:
AUPH has been bouncing since FDA approval, when it goes over 15, I sell a small position when it goes down in the 12-13 range , I buy it back, total no brainer since It happens so often. When the stock goes above 15 and stays there, I”ll be done flipping.
Instead of complaining , I’m adding to my position, with no money out of pocket ……..by the way, it just happened again today.
With everything going on, all the biotechs are dancing around, look at SRNE it’s the same boat.
Good point Zzat, that’s why you only flip 10% of your position. Bio stocks are extremely volatile before they head north permanently , and trust me it really breaks the monotony of just waiting.